Nuformix (NFX) Competitors GBX 0.05 0.00 (-8.00%) (As of 12/20/2024 12:01 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors NFX vs. OCTP, OVB, PEBI, VAL, ABZA, VER, HEMO, BTG, ABC, and ONTShould you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Oxford Cannabinoid Technologies (OCTP), Ovoca Bio (OVB), Port Erin Biopharma Investments (PEBI), ValiRx (VAL), Abzena (ABZA), Vernalis (VER), Hemogenyx Pharmaceuticals (HEMO), BTG (BTG), Abcam (ABC), and Oxford Nanopore Technologies (ONT). These companies are all part of the "biotechnology" industry. Nuformix vs. Oxford Cannabinoid Technologies Ovoca Bio Port Erin Biopharma Investments ValiRx Abzena Vernalis Hemogenyx Pharmaceuticals BTG Abcam Oxford Nanopore Technologies Nuformix (LON:NFX) and Oxford Cannabinoid Technologies (LON:OCTP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends. Does the media refer more to NFX or OCTP? In the previous week, Nuformix's average media sentiment score of 0.00 equaled Oxford Cannabinoid Technologies'average media sentiment score. Company Overall Sentiment Nuformix Neutral Oxford Cannabinoid Technologies Neutral Do insiders and institutionals have more ownership in NFX or OCTP? 0.1% of Nuformix shares are held by institutional investors. Comparatively, 14.1% of Oxford Cannabinoid Technologies shares are held by institutional investors. 12.4% of Nuformix shares are held by insiders. Comparatively, 29.8% of Oxford Cannabinoid Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has stronger earnings and valuation, NFX or OCTP? Nuformix has higher revenue and earnings than Oxford Cannabinoid Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuformix£50K7.54-£1.20MN/AN/AOxford Cannabinoid TechnologiesN/AN/A-£4.24MN/AN/A Which has more risk and volatility, NFX or OCTP? Nuformix has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Oxford Cannabinoid Technologies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Does the MarketBeat Community favor NFX or OCTP? Nuformix received 68 more outperform votes than Oxford Cannabinoid Technologies when rated by MarketBeat users. CompanyUnderperformOutperformNuformixOutperform Votes6866.67% Underperform Votes3433.33% Oxford Cannabinoid TechnologiesN/AN/A Is NFX or OCTP more profitable? Nuformix's return on equity of -27.25% beat Oxford Cannabinoid Technologies' return on equity.Company Net Margins Return on Equity Return on Assets NuformixN/A -27.25% -17.20% Oxford Cannabinoid Technologies N/A -86.76%-53.92% SummaryNuformix beats Oxford Cannabinoid Technologies on 7 of the 9 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Nuformix News Delivered to You Automatically Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NFX vs. The Competition Export to ExcelMetricNuformixBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£377,000.00£165.68M£5.14B£1.90BDividend YieldN/A3.64%5.09%5.55%P/E Ratio-1.63115.5190.051,821.81Price / Sales7.5418,531.021,117.09386,342.76Price / Cash3.5512.8743.1028.54Price / BookN/A8.594.782.78Net Income-£1.20M-£20.67M£120.31M£157.16M7 Day PerformanceN/A-1.05%-1.92%-2.00%1 Month PerformanceN/A174.77%13.65%21.23%1 Year PerformanceN/A134.18%28.34%29.20% Nuformix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NFXNuformixN/AGBX 0.05-8.0%N/A-83.6%£377,000.00£50,000.00-1.633Gap UpOCTPOxford Cannabinoid TechnologiesN/AGBX 0.12-4.2%N/AN/A£1.25MN/A-53.107Gap DownOVBOvoca BioN/AGBX 1.50-3.2%N/A+78.7%£1.22MN/A-38.755Gap DownPEBIPort Erin Biopharma InvestmentsN/AGBX 4.50+∞N/AN/A£1.04M£28,300.00-6.43N/AGap UpVALValiRxN/AGBX 0.72-1.4%N/A-88.3%£946,000.00N/A-36.255,450ABZAAbzenaN/AGBX 15.75flatN/AN/A£0.00N/A0.00N/AVERVernalisN/AGBX 6.17flatN/AN/A£0.00N/A0.00350HEMOHemogenyx PharmaceuticalsN/AGBX 343.77-9.1%N/A+16,252.4%£4.61BN/A-28,400.0014High Trading VolumeBTGBTGN/AGBX 840+0.1%N/AN/A£3.26B£914.10M29.474,690News CoverageABCAbcamN/AGBX 1,226+11.2%N/AN/A£2.81B£350.40M20,433.331,650Gap UpHigh Trading VolumeONTOxford Nanopore Technologies1.55 of 5 starsGBX 156.60-0.3%GBX 235.50+50.4%-30.7%£1.47B£167.75M-785.001,281Positive News Related Companies and Tools Related Companies OCTP Alternatives OVB Alternatives PEBI Alternatives VAL Alternatives ABZA Alternatives VER Alternatives HEMO Alternatives BTG Alternatives ABC Alternatives ONT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:NFX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuformix plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuformix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.